Catumaxomab, a rat-mouse hybrid targeting epithelial cell adhesion molecule (EpCAM) and CD3, and blinatumomab, a mouse antibody targeting CD19 and CD3, have been approved by the FDA for treating malignant ascites and acute lymphoblastic leukemia, respectively. Here, CD19 is linked to acute lymphoblastic leukemia.